Passage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference
Passage Bio, Inc. (Nasdaq: PASG) has announced that CEO Bruce Goldsmith will participate in a fireside chat at the Guggenheim 3rd Annual Neuro/Immunology Conference on November 16, 2021, at 3:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Passage Bio, Inc. (Nasdaq: PASG) has announced that CEO Bruce Goldsmith will participate in a fireside chat at the Guggenheim 3rd Annual Neuro/Immunology Conference on November 16, 2021, at 3:00 p.m. ET. This virtual event will feature discussions on the company's advancements in genetic therapies for central nervous system disorders. A live webcast will be available on Passage Bio's website, with a replay accessible for 30 days post-event. The company aims to provide transformative genetic medicines and has established a collaboration with the University of Pennsylvania's Gene Therapy Program.
Details
News Market Reaction – PASG
The recorded move for PASG in the trading session of this news was -2.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio, will participate in a fireside chat at the upcoming Guggenheim 3rd Annual Neuro/Immunology Conference being held virtually November 15-16, 2021.
Format: Fireside Chat
Date: Tuesday, November 16, 2021
Time: 3:00 p.m. ET
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the events.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.